Calcifediol Oral Capsule

DRUG3 trials

Sponsors

OPKO Health, Inc., Parc de Salut Mar

Conditions

CKD Stage 3CKD Stage 4Chronic Kidney DiseasesPulmonary Artery HypertensionSecondary Hyperparathyroidism Due to Renal CausesStage 5 Chronic Kidney DiseaseVitamin D DeficiencyVitamin D Insufficiency

Phase 2

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

TerminatedNCT03602261

OPKO Health, Inc.Chronic Kidney Diseases, Secondary Hyperparathyroidism Due to Renal Causes, Stage 5 Chronic Kidney Disease +1

Start: 2018-07-09End: 2021-02-24Updated: 2026-04-03

Phase 4

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

CompletedNCT03588884

OPKO Health, Inc.CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism Due to Renal Causes +1

Start: 2018-06-08End: 2020-04-24Updated: 2022-12-09

REstoration of VItamin D in Pulmonary Arterial Hypertension

Not yet recruitingNCT06258850

Parc de Salut MarPulmonary Artery Hypertension, Vitamin d Deficiency

Start: 2024-07-01End: 2027-12-31Target: 102Updated: 2024-02-14